Lessons from the Established Status Epilepticus Treatment Trial

Area of Science:

• Neurology
• Emergency Medicine
• Clinical Trials

Background:

• Convulsive status epilepticus (SE) is a common neurological emergency requiring prompt treatment.
• Established SE (ESE) occurs when first-line benzodiazepine treatment fails, necessitating alternative therapies.
• Uncertainty exists regarding the optimal second-line agent for ESE.

Purpose of the Study:

• To compare the effectiveness of valproate (VPA), fosphenytoin (FOS), and levetiracetam (LEV) as second-line treatments for established convulsive SE.
• To gather insights into the practical implementation and ethical considerations of conducting SE trials in emergency settings.

Main Methods:

• The Established Status Epilepticus Treatment Trial (ESETT) was a phase III, double-blind, randomized comparative effectiveness study.
• The trial enrolled patients aged 2 years and above with established convulsive SE.
• It compared three treatment arms: valproate (VPA), fosphenytoin (FOS), and levetiracetam (LEV).

Main Results:

• Enrollment for the ESEETT study was completed in January 2019.
• Results are anticipated later in the current year.
• The study provides valuable data on the comparative effectiveness of VPA, FOS, and LEV for ESE.

Conclusions:

• The ESEETT study is expected to inform clinical practice guidelines for managing established convulsive SE.
• Lessons learned from the trial design and implementation will influence future research in acute seizure management.
• The study addresses critical knowledge gaps in treating refractory SE across pediatric and adult populations.